Review article: The role of the gut–brain axis in inflammatory bowel disease and its therapeutic implications

Summary Background Treatments targeting the gut–brain axis (GBA) are effective at reducing symptom burden in irritable bowel syndrome (IBS). The prevalence of common mental disorders and IBS‐type symptom reporting is significantly higher in inflammatory bowel disease (IBD) than would be expected, suggesting potential GBA effects in this setting. Manipulation of the GBA may offer novel treatment strategies in selected patients with IBD. We present a narrative review of the bi‐directional effects of the GBA in IBD and explore the potential for GBA‐targeted therapies in this setting. Methods We searched MEDLINE, EMBASE, EMBASE Classic, PsychINFO, and the Cochrane Central Register of Controlled Trials for relevant articles published by March 2024. Results The bi‐directional relationship between psychological well‐being and adverse longitudinal disease activity outcomes, and the high prevalence of IBS‐type symptom reporting highlight the presence of GBA‐mediated effects in IBD. Treatments targeting gut–brain interactions including brain–gut behavioural treatments, neuromodulators, and dietary interventions appear to be useful adjunctive treatments in a subset of patients. Conclusions Psychological morbidity is prevalent in patients with IBD. The relationship between longitudinal disease activity outcomes, IBS‐type symptom reporting, and poor psychological health is mediated via the GBA. Proactive management of psychological health should be integrated into routine care. Further clinical trials of GBA‐targeted therapies, conducted in selected groups of patients with co‐existent common mental disorders, or those who report IBS‐type symptoms, are required to inform effective integrated models of care in the future.